Journals / İstanbul Medical Journal / 2021 / Cilt: 22 - Sayı: 4

Mucormycosis in Hematologic Malignancies: Clinical Follow-Up and Treatment Results

Hematolojik Malignitelerde Mukormikozis: Klinik Takip ve Tedavi Sonuçları

Pages
245–249
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Effective and early surgery and antifungal application reduce mortality in mucormycosis by early diagnosis and multidisciplinary approach, without bone destruction in the paranasal sinus computed tomography with recurrent fever and earlystage sinusitis finding by performing a biopsy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Mucormycosis is an aggressive-progressive invasive fungal infection caused by mold fungi in the division of mucorales of the zygomycetes class with high mortality, and is the most common fungal infection in patients with hematologic malignancies.
📊
Key Findings & Data:Methods: This study retrospectively evaluated patients with mucormycosis diagnosis between January 2015 and December 2019, including demographic features, hematologic diseases and comorbidities, radiological evaluations, symptoms and signs, treatments, and outcomes.
💡
Conclusion & Impact:Effective and early surgery and antifungal application reduce mortality in mucormycosis by early diagnosis and multidisciplinary approach, without bone destruction in the paranasal sinus computed tomography with recurrent fever and earlystage sinusitis finding by performing a biopsy.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Mucormycosis is an aggressive-progressive invasive fungal infection caused by mold fungi in the division of mucorales of the zygomycetes class with high mortality, and is the most common fungal infection in patients with hematologic malignancies. Methods: This study retrospectively evaluated patients with mucormycosis diagnosis between January 2015 and December 2019, including demographic features, hematologic diseases and comorbidities, radiological evaluations, symptoms and signs, treatments, and outcomes. Results: Maxillofacial 9/19 (47.37%) of patients and 10/19 (59.9%) rhinoorbital mucor. Hematologic malignancy was observed in 15 (78.95%) patients, whereas others had additional pre-disposing factors, such as diabetes mellitus and chronic renal failure. The most common find-ings were persistent fever, mucopurulent nasal flux, and periorbital edema. Endoscopic sinus surgery + medication was administered in 12/19 (62.2%) patients and antifungal therapy in 7/19 (37.8%). In addition, 15/19 (79.95%) patients died and 4/19 recovered with sequela. Conclusion: The first large-scale mucormycosis study from our country will guide in determining the treatment algorithm. Effective and early surgery and antifungal application reduce mortality in mucormycosis by early diagnosis and multidisciplinary approach, without bone destruction in the paranasal sinus computed tomography with recurrent fever and earlystage sinusitis finding by performing a biopsy.

Özet

Amaç: Mukormikoz, yüksek mortaliteye sahip zigomiset sınıfının mucorales bölümünde yer alan, küf mantarlarının neden olduğu agresif ilerleyen invaziv bir mantar enfeksiyonudur. Hematolojik maligniteli hastalarda en sık görülen mantar enfeksiyonu olarak karşımıza çıkmaktadır. Yöntemler: Çalışmamızda Ocak 2015-Aralık 2019 tarihleri arasında mukormikoz tanısı alan hastalar retrospektif olarak değerlendirildi. Hastaların demografik özellikleri, hematolojik hastalıkları ve komorbiditeleri, radyolojik değerlendirmeleri, semptom ve bulguları, tedavileri ve sonuçları değerlendirildi. Bulgular: Olgularımız 9/19 (%47,37) maksillofasiyal ve 10/19 (%59,9) rinoorbital mukor hastalarıydı. Hastaların 15’inde (%78,95) sadece hematolojik malignite varken, diğerlerinde diabetes mellitus ve kronik böbrek yetmezliği gibi ek predispozan faktörler vardı. En sık görülen bulgular inatçı ateş, mukopürülan burun akısı ve periorbital ödemdi. Hastaların 12/19’u (%62,2) endoskopik sinüs cerrahisi + antifungal tedavi ve 7/19’u (%37,8) sadece antifungal tedavi gördü. Hastaların 15/19’u (%79,95) öldü ve bunların 4/19’u sekel ile iyileşti. Sonuç: Ülkemizden ilk büyük ölçekli mukormikoz çalışması, tedavi algoritmasının belirlenmesi açısından yol gösterici olacaktır. Erken tanı ve multidisipliner yaklaşımla, etkili ve erken cerrahi ve antifungal uygulama ve biyopsi ile, mukormikozda mortalitenin, tekrarlayan ateş ile paranazal sinüs bilgisayarlı tomografide kemik destrüksiyonu olmaksızın, azaltılabileceğini düşünmekteyiz.

🔖

Cite This Article

DOĞU, M. H., KIRGEZEN, T., SARI, N. D., SERİN, İ. (2022). Mucormycosis in Hematologic Malignancies: Clinical Follow-Up and Treatment Results. İstanbul Medical Journal, Cilt: 22 - Sayı: 4, 245–249. https://ajindex.com/articles/551773

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bouza E, Muñoz P, J Guinea J. Mucormycosis: an emerging disease? Clinical Microbiology and Infection 2006; 12(Suppl7): 7-23
  2. Kontoyiannis DP, Lewis RE, Lortholary O, Spellberg B, Petrikkos G, Roilides E, et al. Future directions in mucormycosis research. Clin Infect Dis 2012; 54(Suppl1): S79-85
  3. Slavin M, van Hal S, Sorrell TC, Lee A, Marriott DJ, Daveson K, et al.; Australia and New Zealand Mycoses Interest Group. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect 2015; 21: 490.e1-10
  4. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17: 1855-64
  5. Kontoyiannis DP, Lewis RE. Agents of mucormycosis and Entomophthoramycosis, Mandell GL, Bennett GE, Dolin R, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia, Pa: Churchill Livingstone. 2010; p. 3257-69
  6. Abidi MZ, Sohail MR, Cummins N, Wilhelm M, Wengenack N, Brumble L, et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses 2014; 57: 687- 98
  7. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003; 53: 744-50
  8. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al.; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-67
  9. Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 2016; 16: 730
  10. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin